Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIC-R platform trial for candidate COVID-19 treatments in hospitalized adults
ISRCTN57085639Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- May 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cyclic Peptides → Modified Peptides → Peptides
01
Overview
Phase 2, randomised, open-label trial of bemcentinib, tozorakimab, acalabrutinib and zilucoplan in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Time to clinical improvement. Started May 2020; status: completed.
02
Drugs
bemcentinibtozorakimabacalabrutinibzilucoplan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN57085639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN57085639.